{"organizations": [], "uuid": "574558aae4cb75ab521dc07c81f8993d23edbbae", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "http://si.wsj.net/public/resources/images/BN-KG784_shireb_G_20150913124546.jpg", "site_section": "http://www.wsj.com/news/business", "section_title": "Business &amp; Finance News - Wall Street Journal", "url": "http://www.wsj.com/articles/shires-baxalta-vision-may-be-fading-1445262701", "country": "US", "title": "Shire’s Baxalta Vision May Be Fading", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "Shire’s Baxalta Vision May Be Fading - WSJ", "spam_score": 0.0, "site_type": "news", "published": "2015-10-19T18:08:00.000+03:00", "replies_count": 0, "uuid": "574558aae4cb75ab521dc07c81f8993d23edbbae"}, "author": "Helen Thomas", "url": "http://www.wsj.com/articles/shires-baxalta-vision-may-be-fading-1445262701", "ord_in_thread": 0, "title": "Shire’s Baxalta Vision May Be Fading", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Shire is suffering from blurred vision. U.S. regulators have asked for more information on the London-listed speciality pharmaceuticals company’s dry-eye disease treatment, rather than handing it an early approval.\nThat needn’t be a huge blow. But it adds to the anxiety around Shire since its surprise hostile bid for Baxalta in August.\nTo be sure, Lifitegrast, which some analysts forecast could generate annual sales of up to... To Read the Full Story, Subscribe or Sign In", "external_links": [], "published": "2015-10-19T18:08:00.000+03:00", "crawled": "2015-10-19T17:38:24.110+03:00", "highlightTitle": ""}